Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $24 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BHVN Hot Sheet
Price: $15.16 -1.69%
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Rating Summary:
16 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 23 | Down: 26 | New: 23
Join SI Premium – FREE
JPMorgan analyst Tessa Romero lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $24.00 (from $27.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biohaven Pharma (BHVN) PT Raised to $32 at Canaccord
- Biohaven Pharma (BHVN) Misses Q3 EPS by 25c
- Marvell (MRVL) PT Lowered to $275 at B.Riley
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
